[go: up one dir, main page]

SG11201803474UA - Vaccines against hepatitis b virus - Google Patents

Vaccines against hepatitis b virus

Info

Publication number
SG11201803474UA
SG11201803474UA SG11201803474UA SG11201803474UA SG11201803474UA SG 11201803474U A SG11201803474U A SG 11201803474UA SG 11201803474U A SG11201803474U A SG 11201803474UA SG 11201803474U A SG11201803474U A SG 11201803474UA SG 11201803474U A SG11201803474U A SG 11201803474UA
Authority
SG
Singapore
Prior art keywords
virus
vaccines against
against hepatitis
hepatitis
vaccines
Prior art date
Application number
SG11201803474UA
Inventor
Thomas Monath
Katherine Cohen
Vera Baumgartl-Strasser
Original Assignee
Hookipa Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech Ag filed Critical Hookipa Biotech Ag
Publication of SG11201803474UA publication Critical patent/SG11201803474UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10041Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG11201803474UA 2015-11-04 2016-11-03 Vaccines against hepatitis b virus SG11201803474UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250639P 2015-11-04 2015-11-04
PCT/EP2016/076591 WO2017076988A1 (en) 2015-11-04 2016-11-03 Vaccines against hepatitis b virus

Publications (1)

Publication Number Publication Date
SG11201803474UA true SG11201803474UA (en) 2018-05-30

Family

ID=57249796

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803474UA SG11201803474UA (en) 2015-11-04 2016-11-03 Vaccines against hepatitis b virus

Country Status (19)

Country Link
US (2) US11214598B2 (en)
EP (2) EP4177348A1 (en)
JP (3) JP6914950B2 (en)
CN (2) CN108779472B (en)
AU (2) AU2016348675B2 (en)
CA (1) CA3003557A1 (en)
DK (1) DK3371316T3 (en)
ES (1) ES2934698T3 (en)
FI (1) FI3371316T3 (en)
HR (1) HRP20221474T1 (en)
HU (1) HUE060648T2 (en)
IL (2) IL314371A (en)
LT (1) LT3371316T (en)
MX (2) MX2018005569A (en)
PL (1) PL3371316T3 (en)
PT (1) PT3371316T (en)
SG (1) SG11201803474UA (en)
SI (1) SI3371316T1 (en)
WO (1) WO2017076988A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2238255T3 (en) 2007-12-27 2013-11-18 Univ Zuerich REPLICATION DEFECTS ARENAVIRUS VECTORS
PL3077519T3 (en) 2013-12-03 2021-10-18 Hookipa Biotech Gmbh Cmv vaccines
SI3218504T1 (en) 2014-11-13 2020-11-30 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
AU2016274655B2 (en) 2015-06-10 2021-06-17 Hookipa Biotech Gmbh HPV vaccines
MX2018005569A (en) * 2015-11-04 2018-12-19 Hookipa Biotech Ag Vaccines against hepatitis b virus.
AU2016352572B2 (en) 2015-11-12 2023-10-19 Hookipa Biotech Gmbh Arenavirus particles as cancer vaccines
FI3526323T3 (en) 2016-10-14 2023-06-06 Prec Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
JP2022010187A (en) * 2017-02-03 2022-01-14 株式会社三洋物産 Game machine
JP2022010188A (en) * 2017-02-03 2022-01-14 株式会社三洋物産 Game machine
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
MA56523A (en) * 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Co COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODIES
US20220226467A1 (en) * 2019-06-18 2022-07-21 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
PH12021553256A1 (en) 2019-06-25 2022-08-08 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
JP7398556B2 (en) 2019-09-30 2023-12-14 ギリアード サイエンシーズ, インコーポレイテッド HBV vaccine and methods of treating HBV
EP4055173A1 (en) * 2019-11-07 2022-09-14 Universität Basel Vizerektorat Forschung Arenaviruses as vectors
EP4069729B1 (en) 2019-12-06 2025-01-22 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
SI4081305T1 (en) 2019-12-24 2025-03-31 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
AR121620A1 (en) 2020-03-20 2022-06-22 Gilead Sciences Inc 4-C-SUBSTITUTED-2-HALO-2-DEOXIADENOSINE NUCLEOSIDE PRODRUGS AND METHODS OF PREPARATION AND USE THEREOF
IL305965A (en) 2021-03-23 2023-11-01 Hookipa Biotech Gmbh Arenaviruses used in treatments of prostate cancer
US20250034213A1 (en) * 2021-04-21 2025-01-30 La Jolla Institute For Immunology Engineered arenavirus glycoprotein compositions, methods and use thereof
CN113201051B (en) * 2021-04-27 2022-08-02 复旦大学 A kind of hepatitis B virus surface protein mutant and its application in anti-hepatitis B virus
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
CN117396478A (en) 2021-06-23 2024-01-12 吉利德科学公司 diacylglycerol kinase modulating compounds
KR20240023629A (en) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 Diacylglycerol Kinase Modulating Compounds
KR20240023628A (en) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 Diacylglycerol Kinase Modulating Compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
WO2025056782A1 (en) 2023-09-15 2025-03-20 Hookipa Biotech Gmbh Arenavirus formulations, methods and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH1084967A (en) * 1996-09-19 1998-04-07 Fujirebio Inc E antigen of hepatitis B
PL348766A1 (en) * 1998-12-04 2002-06-03 Biogen Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
FR2803599B1 (en) * 2000-01-06 2004-11-19 Inst Nat Sante Rech Med NEW MUTATED HEPATITIS B VIRUS, ITS NUCLEIC AND PROTEIN CONSTITUENTS AND THEIR APPLICATIONS
US20100183652A1 (en) * 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
EP1888622A1 (en) * 2005-05-23 2008-02-20 Oxxon Therapeutics Ltd. Compositions for inducing an immune response against hepatitis b
CN101037476A (en) * 2006-03-15 2007-09-19 复旦大学 Fusion protein for preparing hepatitis B vaccine and its carrier
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
NZ626867A (en) * 2006-12-27 2014-09-26 Harvard College Compositions and methods for the treatment of infections and tumors
DK2238255T3 (en) 2007-12-27 2013-11-18 Univ Zuerich REPLICATION DEFECTS ARENAVIRUS VECTORS
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
JP5897464B2 (en) * 2009-08-07 2016-03-30 トランジェーヌ、ソシエテ、アノニムTransgene S.A. Composition for treating HBV infection
AU2012214394B2 (en) * 2011-02-12 2016-08-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis B infection
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
CN110042110A (en) 2012-01-24 2019-07-23 桑福德健康公司 For treating the polynucleotides of oncogenic virus polypeptide positive tumor
ES2751423T3 (en) 2013-03-15 2020-03-31 Univ Geneve Antimycobacterial vaccines
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
PL3077519T3 (en) 2013-12-03 2021-10-18 Hookipa Biotech Gmbh Cmv vaccines
WO2015183895A1 (en) 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
AU2015321557B2 (en) 2014-09-22 2020-05-14 Regents Of The University Of Minnesota Pichinde virus reverse genetics system and methods of use
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
SI3218504T1 (en) * 2014-11-13 2020-11-30 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
DE102015207036A1 (en) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviruses for use in the treatment and / or prevention of tumors, and methods of producing arenaviruses with (improved) tumor-regressive properties
AU2016274655B2 (en) 2015-06-10 2021-06-17 Hookipa Biotech Gmbh HPV vaccines
WO2017068190A1 (en) 2015-10-23 2017-04-27 Institut Pasteur Recombinant mopeia virus and vaccine platform
MX2018005569A (en) * 2015-11-04 2018-12-19 Hookipa Biotech Ag Vaccines against hepatitis b virus.
AU2016352572B2 (en) 2015-11-12 2023-10-19 Hookipa Biotech Gmbh Arenavirus particles as cancer vaccines
US10980877B2 (en) 2016-04-28 2021-04-20 The University Of Chicago Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen
SG11201810048VA (en) 2016-05-18 2018-12-28 Univ Basel Tri-segmented pichinde viruses as vaccine vectors
JP2019533690A (en) 2016-11-04 2019-11-21 ホオキパ バイオテック ジーエムビーエイチ Replication-deficient arenavirus particles and three-segment arenavirus particles as cancer vaccines
CA3058539A1 (en) 2017-04-07 2018-10-11 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors

Also Published As

Publication number Publication date
WO2017076988A1 (en) 2017-05-11
EP4177348A1 (en) 2023-05-10
JP6914950B2 (en) 2021-08-11
JP2018536433A (en) 2018-12-13
PL3371316T3 (en) 2023-02-13
KR20180082485A (en) 2018-07-18
MX2018005569A (en) 2018-12-19
US20220073568A1 (en) 2022-03-10
HUE060648T2 (en) 2023-04-28
US11214598B2 (en) 2022-01-04
AU2023200108A1 (en) 2023-02-16
AU2016348675A1 (en) 2018-05-17
HK1255847A1 (en) 2019-08-30
IL259077A (en) 2018-06-28
JP2024010027A (en) 2024-01-23
IL314371A (en) 2024-09-01
DK3371316T3 (en) 2023-01-23
IL259077B2 (en) 2024-12-01
BR112018009032A2 (en) 2018-11-06
CN108779472A (en) 2018-11-09
AU2016348675B2 (en) 2022-11-17
BR112018009032A8 (en) 2019-02-26
NZ741950A (en) 2023-10-27
EP3371316B1 (en) 2022-10-19
IL259077B1 (en) 2024-08-01
HRP20221474T1 (en) 2023-01-06
MX2023013140A (en) 2023-11-28
JP2021182922A (en) 2021-12-02
US20180319845A1 (en) 2018-11-08
FI3371316T3 (en) 2023-01-13
CA3003557A1 (en) 2017-05-11
SI3371316T1 (en) 2023-02-28
PT3371316T (en) 2022-11-17
ES2934698T3 (en) 2023-02-24
CN108779472B (en) 2022-09-09
CN115948467A (en) 2023-04-11
LT3371316T (en) 2022-11-25
EP3371316A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
SG11201803474UA (en) Vaccines against hepatitis b virus
LT3718565T (en) Respiratory virus vaccines
SI3393510T1 (en) Zika virus vaccine
SG10201913630YA (en) Zika virus vaccine
ZA201700165B (en) Influenza virus vaccines and uses thereof
GB201406608D0 (en) Virus
GB201613191D0 (en) Zika virus vaccine
SG11201610443WA (en) Influenza virus vaccines and uses thereof
IL263550A (en) Vaccine against infectious bronchitis virus
GB201419572D0 (en) Virus
SG11201808268UA (en) Recombinant hansenula-based high dosage hepatitis b vaccine
EP3500280A4 (en) VIRUS Vaccines
GB201702193D0 (en) Hepatitis E virus vaccine
IL254648A0 (en) Vaccines based on hepatitis b core antigens
HK40093198A (en) Vaccines against hepatitis b virus
HK40090610A (en) Vaccines against hepatitis b virus
GB201605099D0 (en) HCV vaccines
SG11201507455WA (en) Hepatitis b virus vaccines
GB201615311D0 (en) Virus, Vaccine cures
PT3393510T (en) Zika virus vaccine
HK1259941A1 (en) Respiratory virus vaccines
IL249705A0 (en) Influenza virus vaccines and uses thereof
IL249704A0 (en) Influenza virus vaccines and uses thereof
GB201522013D0 (en) Virus
GB201600380D0 (en) Modified virus